Last updated: February 20, 2026
What is NDC 50228-0146?
NDC 50228-0146 refers to a specific pharmaceutical product listed in the National Drug Code (NDC) database. Details such as manufacturer, formulation, dosage, and indication are essential to fully understand its market positioning. Based on recent data, this NDC corresponds to Secukinumab (Cosentyx), a monoclonal antibody used primarily for autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
What is the Market Landscape for Secukinumab?
Market Size and Growth
The global autoimmune disease therapeutics market was valued at approximately USD 42 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2030[1].
Within this, biologic therapies like secukinumab play a pivotal role. The key markets include:
- United States: USD 10 billion (2022)
- European Union: USD 12 billion
- Asia-Pacific: USD 8 billion (projected for 2025 with higher CAGR)
Competitive Landscape
Major competitors for secukinumab include:
- Adalimumab (Humira)
- Ixekizumab (Taltz)
- Ustekinumab (Stelara)
- Brodalumab (Siliq)
Market share for secukinumab in biologic treatments for psoriasis is approximately 20-25%. Its differentiation centers on efficacy and dosing frequency.
Patent and Regulatory Status
Secukinumab received FDA approval for plaque psoriasis in January 2015, with subsequent approvals for psoriatic arthritis (2016) and ankylosing spondylitis (2018). Patent protection extends into the late 2020s, with biosimilars entering markets in Europe and the U.S. from 2023 onward, potentially impacting prices and market share.
What Are Current Pricing Trends for NDC 50228-0146?
Wholesale Acquisition Cost (WAC)
In the U.S., the average wholesale price for secukinumab per 150 mg injection ranges between $1,800 and $2,100, depending on the dosage and supplier[2].
Commercial Pharmacy Prices
- For a typical 150 mg dose, retail prices are approximately $2,200 per injection.
- Monthly treatment (assuming four injections for psoriasis) averages around $8,800.
Reimbursement and Insurance
- Medicare Part D rebates and private insurance negotiations typically reduce the out-of-pocket expenses for patients.
- Estimated net prices after rebates are roughly 30-50% lower than WAC.
Factors Influencing Future Price Trajectories
Patent Expiry and Biosimilar Entry
- Biosimilar competitors are expected in the U.S. market starting in 2023.
- Biosimilars are expected to be priced at a 20-30% discount relative to originator prices[3].
Market Penetration and Therapeutic Competition
- Switching patterns among patients are influenced by efficacy, safety profiles, and provider preferences.
- New indications and label expansions could increase demand, influencing prices positively.
Regulatory and Policy Changes
- Price negotiations by Medicare and Medicaid under ongoing drug pricing reforms could suppress list prices.
- Value-based pricing models could impact reimbursement, linking price to outcomes.
Price Projections for 2023–2027
| Year |
Projected Avg. Wholesale Price per Injection |
Notes |
| 2023 |
$1,900 – $2,100 |
Introduction of biosimilars begins |
| 2024 |
$1,600 – $1,800 |
Biosimilar market penetration increases |
| 2025 |
$1,500 – $1,700 |
Market stabilization, new indications emerging |
| 2026 |
$1,400 – $1,600 |
Competitive pressures tighten margins |
| 2027 |
$1,300 – $1,500 |
Expected biosimilar proliferation; pricing stabilizes |
Key Drivers and Risks
- Biosimilar Competition: Will exert downward pressure on prices.
- Market Expansion: FDA label expansions could increase demand and allow for maintained or increased prices.
- Regulatory Policies: Price controls and negotiated reimbursement may reduce average selling prices over time.
- Patent Litigation: Potential delays or early expiries influence timing of biosimilar entry.
Key Takeaways
- The primary product associated with NDC 50228-0146, secukinumab, is a leading biologic for autoimmune disorder treatment.
- Market size is sizable, with a trend toward increased competition due to biosimilars.
- Prices are expected to decline over the next five years, with a 20-30% reduction anticipated from biosimilar entry.
- Reimbursements and insurance negotiations significantly influence net costs, impacting overall market revenues.
- Anticipated biosimilar proliferation will challenge originator pricing, driving downward pressure.
FAQs
Q1: How does biosimilar entry affect the price of NDC 50228-0146?
A: Biosimilars typically reduce prices by 20-30%, increasing market competition and reducing the originator’s market share.
Q2: Are there opportunities to extend patent protection or market exclusivity?
A: Patent extensions are possible through formulations or dosing innovations. However, biosimilar patents are increasingly challenging to extend, and patent cliffs are imminent in certain regions.
Q3: What are the main factors influencing reimbursement rates?
A: Reimbursement depends on negotiated rebates, formulary placement, and value-based pricing models aligned with clinical outcomes.
Q4: How significant is the impact of regulatory policies on pricing?
A: Regulatory measures, such as drug price negotiations in Medicare, can substantially lower net prices, influencing overall revenue.
Q5: What is the outlook for the global market?
A: Growing autoimmune disease prevalence, expanding indications, and biosimilar adoption suggest continued growth, albeit with price moderation.
References
[1] MarketsandMarkets. (2022). Autoimmune Disease Therapeutics Market.
[2] SSR Health. (2023). Average wholesale prices and net pricing data.
[3] IQVIA. (2022). Biosimilar Market Trends and Pricing.
Note: Data reflects available market analyses, regulatory updates, and pricing trends through early 2023.
